Silence Therapeutics PLC
NASDAQ:SLN
Silence Therapeutics PLC
PP&E Gross
Silence Therapeutics PLC
PP&E Gross Peer Comparison
Competitive PP&E Gross Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Silence Therapeutics PLC
NASDAQ:SLN
|
PP&E Gross
£611k
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
PP&E Gross
$13m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
PP&E Gross
$95.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
PP&E Gross
$24.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
PP&E Gross
£42.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
PP&E Gross
£509.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Silence Therapeutics PLC's PP&E Gross?
PP&E Gross
611k
GBP
Based on the financial report for Dec 31, 2019, Silence Therapeutics PLC's PP&E Gross amounts to 611k GBP.
What is Silence Therapeutics PLC's PP&E Gross growth rate?
PP&E Gross CAGR 3Y
-24%
Over the last year, the PP&E Gross growth was -34%. The average annual PP&E Gross growth rates for Silence Therapeutics PLC have been -24% over the past three years .